

5 Tips for Managing Canine Allergies With Zenrelia™ (ilunocitinib tablets)

Zenrelia™ (ilunocitinib tablets) offers veterinarians an option to relieve itching and inflammation in their canine patients. Andrew Rosenberg, DVM, DACVD, shares 5 key tips for integrating Zenrelia into your allergy management toolbox. Scan the QR code below to hear the full Vet2Vet conversation between Dr. Rosenberg and Cassi Fleming, MS, DVM.

1. Think Beyond the Clinical Signs

When a dog is severely itchy, everything suffers, including sleep, comfort and the human-animal bond. Using Zenrelia controls the itch, making it easier for families to reconnect and enjoy everyday life together.

2. Emphasize Simple Dosing

Once-daily dosing, without a need for loading or tapering, sets Zenrelia apart from other Janus kinase inhibitors. Simple and clear once daily dosing that does not change over time can help improve compliance.

3. Plan Around Vaccinations

Zenrelia affects the immune response, so it should not be given to patients concurrently with any vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia.

4. Highlight Individual Differences

Not all allergy patients are the same, even if they have similar clinical presentations. Each dog's cytokine profile is unique, meaning it will respond differently to various therapies. Some patients who have failed similar therapies have had success with Zenrelia.

5. Monitor Success Comprehensively

Ask pet owners to monitor their pet's quality of life rather than focusing only on the skin's appearance. Improved sleep, reduced scratching, and better overall comfort are also important indicators of successful therapy. Objective tools like the pruritus visual analog scale (PVAS) can help clients track progress over time.



[Scan and listen to the full discussion on VetFolio](#)

INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1-888-545-5973 or visit www.elancoelabels.com/us/zenrelia.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. **Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.** Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. ©2025 Elanco or its affiliates. PM-US-25-0931

Brought to you by Elanco Animal Health ■ ZenreliaForVets.com

For more information on Zenrelia, please see full prescribing information on page 50.

Canine itch tracker

Score treatment success.

Zenrelia™
(ilunocitinib tablets)

Relief for itchy skin is within reach.

Use this scale to monitor itch levels and help get dogs back to normal.

10

Extreme itching (severe/continuous itching).

My patient does not stop itching irrespective of surroundings or commands, and needs to be physically restrained from itching.

8–9

Severe itching (prolonged episodes).

Itching disrupts sleep, eating, play, and exercise. Itching continues even when my patient is distracted.

6–7

Moderate itching (frequent episodes).

Patient is itchy periodically through the day, but not when eating, playing, exercising, or being distracted. Itching occurs at night when observed.

4–5

Mild itching (semi-frequent episodes).

Patient does not itch when eating, playing, exercising, or being distracted.

2–3

Very mild itching (occasional episodes).

Patient is only slightly itchier than what I consider normal.

0–1

Normal dog.

Itching is not a problem for my patient.

STRIVE FOR NORMAL

INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancoLabels.com/us/zenrelia.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES.

Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.